These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33775123)

  • 1. Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial.
    Mäki-Petäjä KM; McGeoch A; Yang LL; Hubsch A; McEniery CM; Meyer PAR; Mir F; Gajendragadkar P; Ramenatte N; Anandappa G; Santos Franco S; Bond SJ; Schönlieb CB; Boink Y; Brune C; Wilkinson IB; Jodrell DI; Cheriyan J
    Hypertension; 2021 May; 77(5):1591-1599. PubMed ID: 33775123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
    Kummar S; Srivastava AK; Navas T; Cecchi F; Lee YH; Bottaro DP; Park SR; Do KT; Jeong W; Johnson BC; Voth AR; Rubinstein L; Wright JJ; Parchment RE; Doroshow JH; Chen AP
    Invest New Drugs; 2021 Dec; 39(6):1577-1586. PubMed ID: 34180036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib.
    Tatsumichi T; Tanaka H; Okazaki T; Takahashi K; Suzuki K; Kawakita K; Houchi H; Kuroda Y; Kosaka S
    J Clin Pharm Ther; 2021 Feb; 46(1):223-226. PubMed ID: 33044009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concise drug review: pazopanib and axitinib.
    van Geel RM; Beijnen JH; Schellens JH
    Oncologist; 2012; 17(8):1081-9. PubMed ID: 22733795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study.
    Erman M; Biswas B; Danchaivijitr P; Chen L; Wong YF; Hashem T; Lim CS; Karabulut B; Chung HJ; Chikatapu C; Ingles S; Slimane K; Kanesvaran R
    BMC Cancer; 2021 Sep; 21(1):1021. PubMed ID: 34521387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
    Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V
    Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
    Maráz A; Bodrogi I; Csejtei A; Dank M; Géczi L; Küronya Z; Mangel L; Petrányi A; Szûcs M; Bodoky G
    Magy Onkol; 2013 Sep; 57(3):173-6. PubMed ID: 24107823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.
    Pili R; Qin R; Flynn PJ; Picus J; Millward M; Ho WM; Pitot H; Tan W; Miles KM; Erlichman C; Vaishampayan U
    Clin Genitourin Cancer; 2013 Dec; 11(4):477-83. PubMed ID: 23891158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.
    Jasim S; Suman VJ; Jimenez C; Harris P; Sideras K; Burton JK; Worden FP; Auchus RJ; Bible KC
    Endocrine; 2017 Aug; 57(2):220-225. PubMed ID: 28685225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of pazopanib for local and lung metastases in Stewart-Treves syndrome.
    Hayashi M; Makino T; Mori N; Mizawa M; Shimizu T
    Eur J Dermatol; 2020 Feb; 30(1):68-69. PubMed ID: 32250262
    [No Abstract]   [Full Text] [Related]  

  • 11. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
    Bible KC; Suman VJ; Molina JR; Smallridge RC; Maples WJ; Menefee ME; Rubin J; Karlin N; Sideras K; Morris JC; McIver B; Hay I; Fatourechi V; Burton JK; Webster KP; Bieber C; Traynor AM; Flynn PJ; Cher Goh B; Isham CR; Harris P; Erlichman C;
    J Clin Endocrinol Metab; 2014 May; 99(5):1687-93. PubMed ID: 24606083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pazopanib induced pigmented lesions of the scrotum and the face in a patient with metastatic renal cancer.
    Kostaki M; Stathopoulou A; Plaka M; Zaras A; Chatzidimitriou E; Dimitrakopoulou A; Christofidou E; Polydorou D; Stratigos A
    J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):e361-e362. PubMed ID: 31066082
    [No Abstract]   [Full Text] [Related]  

  • 13. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors.
    Goh BC; Reddy NJ; Dandamudi UB; Laubscher KH; Peckham T; Hodge JP; Suttle AB; Arumugham T; Xu Y; Xu CF; Lager J; Dar MM; Lewis LD
    Clin Pharmacol Ther; 2010 Nov; 88(5):652-9. PubMed ID: 20881954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy in renal carcinoma: a case of long-term effect with complete control of toxicity.
    Conforti S; Ceniti S; Conforti L; Turano S; Minardi S; Palazzo S
    Tumori; 2014; 100(6):e293-7. PubMed ID: 25688514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity.
    Schinzari G; Monterisi S; Signorelli D; Cona MS; Cassano A; Danza F; Barone C
    Tumori; 2014; 100(6):e298-300. PubMed ID: 25688515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.
    Kasper B; Sleijfer S; Litière S; Marreaud S; Verweij J; Hodge RA; Bauer S; Kerst JM; van der Graaf WTA
    Ann Oncol; 2014 Mar; 25(3):719-724. PubMed ID: 24504442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
    Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
    Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case report of a long-surviving man with metastatic renal cell carcinoma treated with pazopanib.
    Ratta R; Santini D
    Tumori; 2014; 100(2):e59-62. PubMed ID: 24852879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial exploration of oral pazopanib in healthy participants and patients with age-related macular degeneration.
    McLaughlin MM; Paglione MG; Slakter J; Tolentino M; Ye L; Xu CF; Suttle AB; Kim RY
    JAMA Ophthalmol; 2013 Dec; 131(12):1595-601. PubMed ID: 24113783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer.
    Sridhar SS; Joshua AM; Gregg R; Booth CM; Murray N; Golubovic J; Wang L; Harris P; Chi KN
    Clin Genitourin Cancer; 2015 Apr; 13(2):124-9. PubMed ID: 24993934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.